Skip to main content
. 2022 Oct 24;12:1037934. doi: 10.3389/fonc.2022.1037934

Figure 4.

Figure 4

T7011 virus effectively expresses CCL5 in tumor tissue and delivers CD19 and BCMA to solid tumors in vivo. (A) Visualization of CD19 and BCMA expression via immunofluorescence microscopy. HEp-2 xenograft tumor tissues were harvested at pre-dose (Mock), 8h, Day 3 (D3), Day 6 (D6), Day 13 (D13), Day 20 (D20), or Day 25 (D25) after intratumoral injection of T7011 at 1×105 PFU/animal and processed for immunofluorescence assay as described in Methods and Materials. The expression of CD19 (green) and BCMA (red) was detected using a designed specific antibody, respectively. The nucleus was stained by DAPI (blue). The images were captured and processed using a NanoZoomer-HT 2.0 Image system. Scale bars = 10 μm. (B) Detection of CCL5 expression in tumor tissue by ELISA. HEp-2 xenograft tumor tissues were harvested and homogenized at pre-dose (D0) and Day 3 (D3), Day 6 (D6), Day 13 (D13), Day 20 (D20), or Day 25 (D25) after intratumoral injection of T7011 at 1×105 PFU/animal (n=3 per time point). The CCL5 expression was detected by ELISA assay. The result is reported as fold change after normalization to the D0 group and presented as mean ± SEM.